The sitagliptin group achieved more rapid reductions in blood glucose levels and higher FPG compliance rates and showed a trend towards reductions in body weight and BMI, with a similar risk of hypoglycemia.
← all excerpts
Comparative efficacy and safety of sitagliptin or gliclazide combined with metformin in treatment-naive patients with type 2 diabetes: A single-center, prospective, randomized, controlled, noninferiority study with genetic polymorphism analysis.
1
—
—